An inexpensive first-line treatment for type 2 diabetes may also reduce heart disease in those with type 1 diabetes

June 12, 2017
An inexpensive first-line treatment for type 2 diabetes may also reduce heart disease in those with type 1 diabetes
Credit: University of Glasgow

An inexpensive first-line treatment for type 2 diabetes may also reduce heart disease in those with type 1 diabetes, according to a new global trial led by the University of Glasgow.

The REMOVAL trial's results, announced today at the American Diabetes Association's 77th Scientific Sessions conference in San Diego, and published in the journal The Lancet Diabetes and Endocrinology, shows how the drug has potentially beneficial effects on cardiovascular and metabolic outcomes in adults with longstanding type 1 .

Currently metformin is recommended for use in those with type 1 diabetes to reduce insulin requirement and stabilise weight, but its effects on the heart and blood vessels in this condition have been unknown. Heart disease is the most common cause of reduced life expectancy in people with type 1 diabetes. In Scotland only 15% of adults with type 1 diabetes have ever received metformin, and only 8% are taking it at any one time.

The REMOVAL trial is the largest clinical trial of metformin therapy in type 1 diabetes to date and has provided clinically meaningful data on metformin's potential to reduce the risk of developing cardiovascular disease.

Study lead Prof John Petrie, from the University of Glasgow's Institute of Cardiovascular and Medical Sciences, said: "The results from this trial are significant because currently cardiovascular disease is a major cause of reduced life expectancy in type 1 diabetes, and cardiovascular disease rates are more than double those of the background population.

"Type 1 diabetes is not caused by lifestyle issues. Insulin therapy is required to control glucose and reduce complications but can cause weight gain which in turn is associated with high cholesterol. This may be one of the reasons that cardiovascular complications remain such a problem for people with type 1 diabetes."

He added: "Our results showed a reduction in the progression of atherosclerosis (thickening of the arteries) in adults with type 1 diabetes, meaning there is now a stronger case to use metformin more widely as a long-term strategy to reduce risk in those with type 1 diabetes, mirroring its use in type 2 diabetes."

The primary objective of the trial was to test whether up to three years treatment with metformin 1000 mg twice daily (added to standard insulin therapy) reduced the risk of heart disease in adults over 40 with longstanding type 1 diabetes and an increased risk for .

The trial looked at 428 men and women the UK, USA, Australia, Canada, Denmark and the Netherlands with type 1 diabetes for five years or more. Of 428 randomised, 219 were allocated metformin and 209 placebos.

The conclusions were drawn over three years, using annual ultrasound scans to measure thickening in the large blood vessels (carotid arteries) as a marker of heart disease; and looking at important positive secondary outcomes related to weight, insulin dose and cholesterol levels.

Karen Addington, UK Chief Executive of the type 1 diabetes charity JDRF, which funded the study, said: "People with type 1 diabetes are living longer, healthier lives than ever before. However complications such as are, naturally, a concern for many families affected by the condition.

"We are committed to eradicating type 1 diabetes and its complications. Findings such as these are crucial in developing ways of using an accessible drug such as Metformin to ensure people living with type 1 stay healthy for longer."

The paper, Cardiovascular and metabolic effects of metformin in type 1 diabetes (REMOVAL): a double-masked, randomised placebo-controlled trial' is published in The Lancet Diabetes and Endocrinology. The research was funded by JDRF (a charity devoted to funding research to cure, treat and prevent type 1 diabetes).

Explore further: ADA recommends metformin as the preferred drug treatment for type 2 diabetes

More information: John R Petrie et al. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial, The Lancet Diabetes & Endocrinology (2017). DOI: 10.1016/S2213-8587(17)30194-8

Related Stories

ADA recommends metformin as the preferred drug treatment for type 2 diabetes

March 13, 2017
The American Diabetes Association (ADA) recommends metformin as the first-line treatment for type 2 diabetes. Metformin monotherapy should be initiated at the time of diagnosis for most patients unless there are contraindications. ...

Metformin use linked to less vitamin B12 measurement

February 17, 2017
(HealthDay)—Long-term metformin use is associated with lower serum vitamin B12 concentration, although metformin users are less likely to receive vitamin B12 testing, according to a study published online Feb. 9 in the ...

Older drug may help type 1 diabetics' heart health

September 6, 2016
(HealthDay)—An inexpensive medication normally given to people with type 2 diabetes may help preserve heart health in people with the less common form of diabetes—type 1, a small new study finds.

Vildagliptin, metformin have different effects on BP in T2DM

March 8, 2017
(HealthDay)—For patients with type 2 diabetes, vildagliptin lowers blood pressure (BP) and elevates heart rate (HR), while metformin increases HR with no effect on BP during intraduodenal (ID) glucose infusion, according ...

Drug combination could help reduce risk of death in type 2 diabetes

May 5, 2016
People with type 2 diabetes treated with insulin plus metformin had a reduced risk of death and major cardiac events compared with people treated with insulin alone, a new study by Cardiff University shows.

Study seeks to reduce cardiovascular risk

December 13, 2011
JDRF-funded researchers have begun enrolling adult patients with type 1 diabetes (T1D) in the REMOVAL study, to test whether metformin—a drug commonly used to treat type 2 diabetes—could help prevent or reduce the ...

Recommended for you

Getting fat to 'talk' again could lower blood glucose and weight

August 22, 2017
Diabetes is a tough disease to manage. Oral medications, insulin shots, close monitoring of blood sugar, dietary changes and exercise can all factor into a person's treatment regimen. Now researchers are exploring a novel, ...

Biochemical 'fingerprints' reveal diabetes progression

August 21, 2017
Researchers from Umeå University in Sweden describe a new method to study biochemical changes that occur in the pancreas during the development of diabetes. The method, recently published in Scientific Reports, is based ...

In a nutshell: Walnuts activate brain region involved in appetite control

August 17, 2017
Packed with nutrients linked to better health, walnuts are also thought to discourage overeating by promoting feelings of fullness. Now, in a new brain imaging study, researchers at Beth Israel Deaconess Medical Center (BIDMC) ...

Smart mat detects early warning signs of foot ulcers

August 16, 2017
While completing his residency in anesthesiology at Massachusetts General Hospital in the mid-2000s, Jon Bloom saw his fair share of foot amputations among patients with diabetes. The culprit: infected foot ulcers.

The best place to treat type 1 diabetes might be just under your skin

August 14, 2017
A group of U of T researchers have demonstrated that the space under our skin might be an optimal location to treat type 1 diabetes (T1D).

New measure of insulin-making cells could gauge diabetes progression, treatment

August 10, 2017
Researchers at the University of Wisconsin-Madison have developed a new measurement for the volume and activity of beta cells, the source of the sugar-regulating hormone insulin.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.